[A comparison between glibenclamide and glipizide in the treatment of type II diabetes].
This study enrolled 36 newly-diagnosed patients with NIDDM, who were divided into two groups, the glibenclamide group and the glipizide group. In each group there were 18 cases, and both group were equal in average age and duration, steam bread tolerance test, GHbA1 and 6 hematological targets were made in both groups before and after administration with glibenclamide or glipizide. The results were as follows: (1) The hypoglycemic effect of glibenclamide was slightly great than that of glipizide. (2) VWF decreased significantly after administration with glibenclamide for 4 months. But in glipizide, only the length of thrombosis formation in vitro was greatly shortened. Thus glibenclamide was better than glipizide, in postponing and reducing microangiopathy complication.
Shi
M Z
MZ
Frist Hospital, Beijing Medical University.
Feng
J G
JG
Zheng
J J
JJ
D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005913:Glipizide / Q000627:therapeutic use*; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects
D001786:Blood Glucose; D005905:Glyburide; D005913:Glipizide